GlassScriptPhysician profile
Wade S Lukken
NPI 1538289772
$4,004.69
in general payments reported to CMS, 2019-2025
24 companies · $1,594 in 2025
The $1,594 reported for 2025 was more than what 96% of Anesthesiology providers received nationally (typical 2025 total: $58.09).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $336 · 2020: $63.06 · 2021: $266 · 2022: $155 · 2023: $164 · 2024: $1,428 · 2025: $1,594.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,970 · Travel and Lodging: $1,215.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,970.14 |
| Travel and Lodging | $1,215.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $2,149.81 | 2022-2025 | Intracept, General - Pain Management |
| Abbott Laboratories | $675.33 | 2019-2025 | Eterna, Proclaim |
| Si-Bone, INC. | $209.85 | 2020-2025 | |
| Abbvie INC. | $139.03 | 2023-2025 | |
| Scilex Pharmaceuticals INC. | $100.54 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $90.08 | 2022-2025 | Ajovy |
| Collegium Pharmaceutical, INC. | $82.77 | 2019-2025 | Belbuca |
| Vertex Pharmaceuticals Incorporated | $77.31 | 2025 | |
| Conetic Solutions, INC. | $75.00 | 2025 | |
| Merck Sharp & Dohme LLC | $64.41 | 2019-2025 | Bridion |
| Averitas Pharma INC. | $52.77 | 2023-2024 | Qutenza |
| Azurity Pharmaceuticals, INC. | $38.58 | 2024 | Horizant |
| Lundbeck LLC | $34.65 | 2022-2023 | Vyepti |
| Tersera Therapeutics LLC | $32.06 | 2019-2022 | |
| Pfizer INC. | $25.97 | 2019-2020 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pacira Therapeutics, INC. | $25.84 | 2019 | |
| Daiichi Sankyo INC. | $20.49 | 2019 | |
| Pacira Pharmaceuticals Incorporated | $18.90 | 2023 | Exparel, Zilretta, Iovera |
| Amgen INC. | $18.81 | 2019 | |
| Impel Pharmaceuticals INC. | $17.21 | 2023 | Trudhesa |
| Takeda Pharmaceuticals U.S.A., INC. | $16.61 | 2025 | Entyvio |
| Arbor Pharmaceuticals, INC. | $14.26 | 2022 | |
| Idorsia Pharmaceuticals US INC | $13.23 | 2023 | Quviviq |
| Biodelivery Sciences International, INC. | $11.18 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Wade Lukken listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.